The mazda pharma Guide 12th August to 18th August 2013 | Page 59
? ? PHARMACEUTICAL NEWS
GLENMARK PHARM SET TO FILE 15-20 NEW PRODUCTS IN US DURING FY'14
Mumbai : Glenmark Pharmaceuticals, a Rs. 5,000 crore plus R&D based pharma major, has planning to file 15-20 new product with international regulatory authorities in the current year. While addressing annual general meeting of shareholder today, Glenn Saldanha, chairman and managing director, said, that the company is spending 8 to 9 per cent of its turnover on research and development activities and will maintain the momentum in the next two to three years. Its 53 products are pending for approval with US FDA and it will get approval for at least 10 products in the current year. There will be no major impact on company's working due to new Drug Price Control Order as the company's very few products are coming under this order. The company is set to achieve growth of around 20 per cent in sales and EBDITA margins are projected at around 22-21 per cent during 2013-14. The depreciation of Indian rupee will likely to assist well in near future. Glenmark entered into an option agreement with Forest Laboratories, USA for collaboration of the development of Novel mPGES-1 inhibitors to treat chronic inflammatory conditions, including pain. It received US$ 9 million and another payment is scheduled to due in 2014. Further, the company's partner, Salix Pharmaceuticals received US FDA approval for Crofelemer in the USA and it is launching it in next few years. The company's specialty business registered strong growth of 27.5 per cent during 2012-13 to Rs. 2,651as compared to Rs. 2,079 crore in the previous year. Its formulation business in India moved up by over 30 per cent to Rs. 1,310 crore from Rs. 1,002 crore. Its market share in cardiology segment improved to 3.30 from 2.86 per cent during 2012-13. Its R&D expenditure increased by 41 per cent to Rs. 412 crore from Rs. 292 crore. It declared equity dividend of 200 per cent for the year 2012-13. Association till date. The tenure of the president is two years. Dileep Kumar is representing drug control officers association in Tamil Nadu. Revi Udaybhaskar from Andhra Pradesh will continue as the Secretary General and Nilesh Gandhi from Maharashtra will work as the Treasurer. The new office-bearers were elected at the executive committee held in Hyderabad. They will assume office in the next annual meeting of the association which will be held in Agarthala in Tripura shortly, said Dileep. The association welcomes the new DPCO which will help the public a lot, he added. Dileep is also the general secretary of Indian Pharmacy Graduates Association, Tamil Nadu branch. AIDCOC has a membership strength of 1500 enforcement officers from across the country.
STRIDES ARCOLAB GETS TENTATIVE ANDA APPROVAL FROM US FDA FOR ANTI AIDS COMBINATION DRUG
Bengaluru : Strides Arcolab Limited has received a tentative approval from the US Food and Drug Administration (FDA) for its anti AIDS combination drug TenofovirDisoproxilFumarate and Emtricitabine tablets, 300mg and 200mg. The Company is one among the six generics companies to have received US FDA approval. This abbreviated new drug application (ANDA) has been reviewed under the expedited provisions of the President's Emergency Plan for AIDS relief (PEPFAR). The company supplies ARV products to global procurement agencies and this approval adds to the over [?\??]?YYX?[?\?]?Z[X?K?H??X?[?][? ?Y??[???\?\?? ??[?[X\?]H[?[] ?X?]X?[?H\? H?[?\?X?\]Z]?[[???[XY??Y[??\?[???? ?]?YH X?] ?[??[ ? [?\? H[?K\?] ??\?[
T??H ?Y?Y[? ?]\?[?X?]Y[???X?[?][? ?]?\?[?K\?] ??\?[Y?[? ??? H ?X]Y[??U?LH[??X?[?[?Y [ ??[??[ \?KX?\?Y? ?Y\?\???X?]?[? ?[?X[?Y?X? \?\?H ?YH ?[??H?T [Y?X?H \?XX?]]X?[ ?? X? ? ?][?[\\?\?? ?\?[H[??X?X?\?H??\[?H\? MX[?Y?X? \?[???X?[]Y\?X???? ?^??[? ?Y\? ?] ?\?[??H?\?
?H??[? ?Y\?[?]?[?Y[?[Y\??[??X\??] ?][ ??\?H??[???[? ?HX[??Y?H ?L \??Y[?\? ????U?SQQP?URT?T?P?U?T?T?PHPS?Q?P?T?S???????P?SUH????K ??S??][X?ZH??]?[YYX??HX[?Y?X? \?\?? ?X?X[ H?[ZX?[ ?[? \?XX?]]X?[ ?\? ?Y?Y[?Y?Y[Y[? ?X?]Z\?HX?]?\?\?XHX[?Y?X? \?[???? ??Y?[??Y?H
??
H?X?[] H[?[] \?[Z[?Y K?H????X?]Z\?][????Y\?][?\???K ??Z[[?[?\??Z[???[?Y ??Y?[?? [X[??X?[?][??[?\??[X??X[ ?[?X? ?H?X?[] H\??Z[??X?]Z\?Y???H] ? \?[?X?]?\??[??\?XH??
X?]?\?K[?Y??[X]H?X?]?\?[??HXY[????[?[?\?X?[? ?X?X[ H \?XX?]]X?[??\[?K???[Y[?[??? \?H]?[?Y[? ??[????\?[ ?\?X[?Y?[??\?X??[??S???]?[YY ?ZY 8?'?H\?H X\?Y ?[???[??H HX?]Z\?][??TT ?????X?[]Y\?\?H \???\??\?[ ? ?]Y?H ?[?H \ HX[ ?\?H ?[ YH?Z[??\?X?]Z\?][?\? \?X?[\? H[\?[??]?[?] ??Y\??\??[?\?Y??Y?H??][][?X[?Y?X? \?[?? ]??B??HSQT?SPT?SP?Q?T?QS??RQ???[??ZH?H[Y\?[X\?\??\?[? ?Y???? ??\?] ?Y??? ????X?H[??[??ZH\??Y[?[X?Y ?\?Y[?? H[[?XH ?Y??? ????X?\??\????X][?
RQ???K?H ?\? ???[??\? H ?X?K\ ?\?Y[?? B?????HPV?QHT?PH?RQH H L?]Y?\? H N]Y?\? ? L??